Breast-cancer drug creates cost dilemma

Article Abstract:

A designer drug has been approved by Health Canada for use in genetic therapy in the treatment of breast cancer. The drug called trastuzumab, marketed under the brand name Herceptin, was developed by San Francisco, CA-based biotechnology firm Genentech Inc which has since then been acquired by Roche Holding AG. The drug is only effective in breast cancer caused by a gene defect that results in overproduction of a protein called HER2, which in turn leads to runaway growth of cancer cells and tumors.

Canada, Product introduction, Anticancer Drugs, Antineoplastic agents, Genentech Inc.

---

Scientists hope to trigger temporary 'vasectomy'

Article Abstract:

University of Leicester researchers have made a breakthrough that may lead to the development of a male contraceptive pill. The British scientists have been using genetic engineering techniques on mice to develop the oral contraceptive.

United Kingdom, Product development, Science & research, Health Care and Social Assistance, Pharmaceutical preparations, Surgical Procedures, HEALTH SERVICES, Oral Contraceptives, Research, Health care industry, Surgery, Contraceptives industry, Vasectomy

---

Similar abstracts:

• Abstracts: DWL secures financing deal. Venture capitalists profit in tech sector. Classwave Wireless wins venture capital deal
• Abstracts: B.C.'s forestry dispute heats up. Interfor lends ear to groups' views
• Abstracts: CN estimates strike cost as much as $40-million. Scotiabank big lender to Warnaco. Harry Potter and the e-commerce revolution
• Abstracts: Bank error in your favour: Collect $17-million. Scotiabank posts record profit for quarter, year. RBC posts record year-end profit
• Abstracts: Cinar denies request for special meeting. Economy needs help to adapt: Dodge

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.